The use of tyrosine kinase inhibition such as sunitinib and monoclonal antibodies targeting anti-angiogenic pathways such as vascular endothelial growth factor (VEGF) signaling has shown antitumoral activity in phase II trials for recurrent meningioma (15, 30, 31). Here, VEGFA is linked to meningioma.